FLUAR FLUAR - A novel solution for fluorescence-guided surgery based on augmented reality
- Coordinator
- Arspectra S.a.r.l., Luxembourg
- Runs
- 1 April 2023 to 31 March 2025
- Status
- Running
- EU funding
- €2.5m
- Total cost
- €3.5m
- Partners
- 1 organisations in 1 countries
- Type
- European Innovation Council
- Grant agreement
- 190144382
What the project is doing
In the project's own words, from its summary on CORDIS.
Fluorescence-guided surgery (FGS) uses near-infrared (NIR) sensors to detect and display fluorescent biomarkers indicating the exact location of tumors. But the current cameras and monitors force surgeons to match the images to the body via subjective comparisons. This long, error-prone process reduces the accuracy, and increases operating times and cost. This is a critical problem in cancer surgery where complete tumor removal is key to prevent recurrence, e.g. a yearly incidence of <0.5 M breast cancer patients requires over 2.8 M surgeries.
FLUAR are novel augmented reality (AR) glasses with integrated high-end NIR sensors and computer vision algorithms. They detect and display the fluorescent biomarkers in the surgeons’ direct sight, hence show the tumor margins on the target. FLUAR will increase the surgeons’ accuracy and reduce tumor removal times. This project aims to finalize and validate FLUAR’s technical developments and clinical usability according to end-user requirements.
Topics
Who is involved
| Organisation | City | Country | Role |
|---|---|---|---|
| Arspectra S.a.r.l. | Mondercange | Luxembourg | Coordinator |
Source: CORDIS, European Commission. Data of 5 Nov 2026, reused under the Commission's reuse policy. View on CORDIS · Grant DOI